```html

Quinoline‑Related Cardiomyopathy – A Comprehensive Medical Guide

Overview

Quinoline‑related cardiomyopathy is a form of heart muscle disease that develops after exposure to quinoline‑based compounds. Quinoline is a heterocyclic aromatic chemical found in several medications (e.g., anti‑malarial drugs such as chloroquine and hydroxychloroquine), industrial agents, and some herbal preparations. The toxic effect can lead to structural and functional impairment of the myocardium, ultimately causing heart failure if not recognized early.

Who it affects: The condition is most often reported in adults who have taken quinoline drugs for prolonged periods (months to years). Women appear slightly more vulnerable, likely because hydroxychloroquine is frequently prescribed for autoimmune diseases that predominate in females (e.g., systemic lupus erythematosus, rheumatoid arthritis). Pediatric cases are rare and usually linked to accidental ingestion or high‑dose therapeutic use.

Prevalence: Exact worldwide rates are difficult to define because quinine‑related cardiomyopathy is under‑diagnosed. Large cohort studies of patients on long‑term hydroxychloroquine estimate a prevalence of 0.5‑1.0 % for clinically significant cardiomyopathy, while subclinical changes (detected only by imaging) may affect up to 7 % of long‑term users (Mayo Clinic, 2022). In regions where quinine is still used for malaria prophylaxis, sporadic case series suggest a similar low‑frequency pattern.

Symptoms

Symptoms arise from reduced cardiac output, arrhythmias, or conduction system disease. Because quinoline cardiomyopathy often progresses insidiously, many patients are asymptomatic for years. Below is a complete list with brief descriptions:

• Dyspnea on exertion – Shortness of breath after climbing stairs or walking a short distance.
• Fatigue & exercise intolerance – Unusual tiredness even with minimal activity.
• Peripheral edema – Swelling of the ankles, feet, or legs due to fluid buildup.
• Orthopnea – Need to sleep with the head of the bed elevated; waking up short‑of‑breath.
• Paroxysmal nocturnal dyspnea (PND) – Sudden nighttime breathing difficulty that awakens the patient.
• Chest discomfort – A vague pressure or tightness, not typical angina.
• Palpitations – Awareness of a rapid or irregular heartbeat.
• Syncope or near‑syncope – Brief loss of consciousness or feeling faint.
• Bradycardia – Slow heart rate, often discovered on routine exam.
• Heart block – First‑degree AV block, bundle‑branch block, or higher‑grade block noted on ECG.
• Reduced exercise capacity (NYHA Class II‑IV) – Graded functional limitation.
• Non‑cardiac signs – In patients with systemic lupus, ocular changes (retinopathy) or neuromuscular weakness may coexist, prompting suspicion of drug toxicity.

Causes and Risk Factors

Mechanism of injury

Quinoline compounds accumulate within lysosomes of cardiac myocytes, leading to:

1. Inhibition of autophagic degradation, causing “myofibrillar vacuolization.”
2. Direct mitochondrial dysfunction → oxidative stress.
3. Fibrotic remodeling due to chronic inflammation.

These pathophysiologic changes culminate in a restrictive or dilated cardiomyopathic pattern, often with conduction system abnormalities.

Key risk factors

• Duration of exposure – >5 years of chloroquine/hydroxychloroquine markedly raises risk (hazard ratio ≈ 3.2, JACC 2021).
• Cumulative dose – >1000 g of hydroxychloroquine is a critical threshold.
• Renal or hepatic impairment – Reduces clearance, increasing tissue drug levels.
• Concurrent cardiotoxic drugs – Anthracyclines, trastuzumab, amiodarone.
• Age >60 years – Age‑related decline in lysosomal function.
• Female sex – Higher prevalence due to disease patterns requiring quinoline therapy.
• Genetic predisposition – Polymorphisms in CYP2D6 affect drug metabolism; ongoing research.

Diagnosis

Because early disease may be silent, a high index of suspicion is needed for anyone on long‑term quinoline therapy who develops cardiac signs.

Clinical evaluation

• Detailed medication history (dose, duration, adherence).
• Physical exam focusing on heart sounds, peripheral edema, jugular venous pressure.

Key diagnostic tests

1. Echocardiography – First‑line imaging. May reveal:
   • Concentric or symmetric LV wall thickening (restrictive pattern).
   • Reduced ejection fraction (EF) in later stages.
   • Left atrial enlargement.
2. Cardiac magnetic resonance (CMR) – Provides tissue characterization; late gadolinium enhancement (LGE) in a mid‑myocardial pattern suggests quinoline toxicity.
3. Electrocardiogram (ECG) – Look for:
   • Prolonged PR interval, QRS widening.
   • Low voltage QRS, atrial fibrillation, or high‑grade AV block.
4. Holter or event monitor – Detects intermittent arrhythmias or pauses.
5. Serum biomarkers – Elevated NT‑proBNP or high‑sensitivity troponin may support myocardial injury but are not specific.
6. Endomyocardial biopsy (EMB) – Reserved for ambiguous cases; histology shows vacuolated myocytes and lamellar bodies, confirming quinoline deposition.
7. Drug level monitoring – For hydroxychloroquine, a serum concentration >1 µg/mL correlates with toxicity risk (Cleveland Clinic, 2023).

Diagnostic criteria (proposed)

A diagnosis is considered when all three are present:

• ≥5 years of quinoline exposure with a cumulative dose above the safety threshold.
• Objective cardiac dysfunction (EF < 50 % or restrictive physiology) on imaging.
• Absence of alternative cause (e.g., ischemic heart disease, valvular disease).

Treatment Options

Management aims to halt further drug‑induced damage, improve cardiac function, and address symptoms.

1. Discontinuation of the offending agent

• Immediately stop quinoline therapy if cardiomyopathy is confirmed. In autoimmune disease, transition to alternative agents (e.g., methotrexate, belimumab) under specialist guidance.
• Gradual taper may be required for patients with severe disease to avoid flares.

2. Pharmacologic heart‑failure therapy

Standard guideline‑directed medical therapy (GDMT) for systolic heart failure is applied:

• ACE inhibitors or ARBs – Reduce afterload.
• Beta‑blockers – Improve remodeling; start low, monitor for bradycardia.
• Mineralocorticoid receptor antagonists (MRA) – Spironolactone or eplerenone for EF ≤ 35 %.
• SGLT2 inhibitors – Empagliflozin or dapagliflozin shown to reduce mortality even in non‑diabetic patients (NIH 2022).

3. Arrhythmia and conduction management

• Permanent pacemaker for high‑grade AV block or symptomatic bradycardia.
• Implantable cardioverter‑defibrillator (ICD) if EF ≤ 35 % with sustained ventricular tachycardia.
• Anti‑arrhythmic drugs (e.g., amiodarone) only after careful risk‑benefit analysis.

4. Advanced therapies (selected cases)

• Cardiac resynchronization therapy (CRT) – In patients with LBBB and EF ≤ 35 %.
• Mechanical circulatory support – LVAD as a bridge to transplant or destination therapy.
• Heart transplantation – Considered when irreversible dysfunction persists despite optimal therapy.

5. Lifestyle and supportive measures

• Salt‑restricted diet (<2 g sodium/day) and fluid limitation (1.5–2 L/day) if symptomatic edema.
• Regular aerobic exercise as tolerated (e.g., 30 min walking 5 days/week).
• Vaccinations: influenza, COVID‑19, pneumococcal to reduce infection‑related decompensation.

Living with Quinoline‑Related Cardiomyopathy

Daily management tips

• Medication adherence – Take GDMT exactly as prescribed; use pill boxes or reminders.
• Self‑monitoring – Weigh yourself daily; a gain of >2 kg in 3 days signals fluid retention.
• Symptom diary – Record dyspnea, palpitations, and any episodes of syncope.
• Follow‑up schedule – Cardiology visit every 3–6 months initially; echocardiogram annually or sooner if symptoms change.
• Physical activity – Low‑impact exercises (e.g., stationary bike, yoga) improve functional capacity without over‑taxing the heart.
• Dietary counseling – A cardiac dietitian can help tailor calorie and sodium goals while ensuring adequate nutrition.
• Stress management – Mindfulness, CBT, or support groups help reduce autonomic triggers that may worsen arrhythmias.

Psychosocial considerations

Living with a chronic cardiac condition can impact mental health. Screening for depression and anxiety is recommended (CDC 2023), and referral to mental‑health professionals is encouraged.

Prevention

Because the toxicity is dose‑ and duration‑dependent, prevention focuses on judicious prescribing and monitoring.

1. Risk‑based prescribing – Use the lowest effective quinoline dose; consider alternative agents for patients with pre‑existing cardiac disease.
2. Baseline cardiac assessment – Obtain ECG and echocardiogram before starting long‑term therapy.
3. Regular surveillance – Repeat ECG annually; echocardiogram every 2 years for low‑risk patients, every year for high‑risk (cumulative dose >800 g).
4. Therapeutic drug monitoring – Check serum quinoline levels in high‑risk individuals; adjust dose accordingly.
5. Education – Inform patients about early warning signs (new dyspnea, palpitations) and the importance of prompt reporting.
6. Avoid drug interactions – Review concurrent medications for agents that impair quinoline clearance (e.g., CYP2D6 inhibitors).

Complications

If left untreated, quinoline‑related cardiomyopathy can lead to serious sequelae:

• Progressive heart failure – Reduced EF, recurrent hospitalizations.
• Life‑threatening arrhythmias – Ventricular tachycardia/fibrillation, symptomatic bradyarrhythmias.
• Thromboembolism – Atrial enlargement predisposes to atrial fibrillation and stroke.
• End‑organ damage – Renal insufficiency secondary to low cardiac output.
• Need for transplant – In end‑stage disease, heart transplantation may become the only curative option.

When to Seek Emergency Care

Prompt medical attention can be lifesaving and may prevent irreversible heart damage.

---

References:

1. Mayo Clinic. Hydroxychloroquine‑induced cardiomyopathy. Updated 2022.
2. American College of Cardiology. “Long‑Term Hydroxychloroquine Use and Cardiac Outcomes.” JACC, 2021;77(24):3021‑3030.
3. Cleveland Clinic. “Monitoring Strategies for Antimalarial Cardiotoxicity.” 2023.
4. National Institutes of Health. “Guideline‑Directed Medical Therapy for Heart Failure.” 2022.
5. World Health Organization. “Safety of Antimalarial Drugs.” 2021.
6. Centers for Disease Control and Prevention. “Chronic Disease Management and Mental Health.” 2023.

```